$2.81
-0.48 (-14.59%)
Open$3.41
Previous Close$3.29
Day High$3.41
Day Low$2.70
52W High$1,210.00
52W Low—
Volume—
Avg Volume322.9K
Market Cap2.71M
P/E Ratio—
EPS$-173.01
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+884.3% upside
Current
$2.81
$2.81
Target
$27.66
$27.66
$20.34
$27.66 avg
$35.38
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.53M | 1.54M | 1.49M |
| Net Income | 146.8K | 155.5K | 142.3K |
| Profit Margin | 9.6% | 10.1% | 9.6% |
| EBITDA | 279.3K | 246.3K | 227.4K |
| Free Cash Flow | 124.0K | 159.2K | 163.1K |
| Rev Growth | +19.5% | +5.1% | +5.0% |
| Debt/Equity | 0.44 | 0.57 | 0.57 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |